Cencora, a leading global pharmaceutical solutions company, has announced a $1 billion investment through 2030 to expand and modernize its U.S. distribution infrastructure. The multiyear plan comes at a time of rising national demand for reliable, high-capacity pharmaceutical delivery systems, underscoring the company’s role in supporting patient access to critical medications.
“Healthcare providers rely on us to ensure patients receive the medications they need,” said Bob Mauch, Cencora President and CEO. “This investment strengthens our distribution backbone and reinforces our commitment to timely, dependable access across the United States.”
Major capacity expansions in Ohio and California
A central component of the investment is a new 530,000-square-foot national distribution center in Harrison, Ohio, slated to be operational by spring 2027. The facility will feature advanced automation, including AI-enabled order processing, robotic handling systems, and autonomous mobile robots.
On the West Coast, Cencora will expand its footprint with a 430,000-square-foot distribution center in Fontana, California, nearly doubling its regional capacity by fall 2026 to support one of the fastest-growing population corridors in the country.
Scaling specialty pharmaceutical distribution
With specialty medicines expected to account for 70% of new drug launches through 2027, Cencora will significantly enhance cold-chain capabilities. Its Dothan, Alabama facility will undergo a major expansion, increasing refrigerated storage by 500% and frozen storage by 200% to accommodate the growing volume of temperature-sensitive therapies.
“As more specialty pharmaceuticals reach the market, these investments will strengthen our ability to support providers and patients nationwide,” said Rich Tremonte, Executive Vice President and President of U.S. Pharmaceuticals and Animal Health.
Reinforcing a critical national supply chain
Cencora currently distributes more than five million medications and healthcare products daily. The new investment advances the company’s long-term strategy to bolster supply chain resilience, integrate advanced automation, and support the next wave of therapeutic innovation.
With this $1 billion commitment, Cencora is positioning itself as a key contributor to a stronger, more reliable U.S. pharmaceutical distribution system.
